News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Study Backs Early Use of Johnson & Johnson’s Remicade in Crohn’s
February 22, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Feb 22 (Reuters) - Treating Crohn's disease by starting people early on drugs that suppress the immune system is more effective than conventional therapy using steroids, according to a study published on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
HIV
Gilead Looks To Simplify HIV Treatment By Combining Two Leading Drugs in One Pill
November 14, 2025
·
2 min read
·
Tristan Manalac
RNA editing
Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal
November 13, 2025
·
3 min read
·
Annalee Armstrong
Obesity
Zealand Freezes Mid-Stage Obesity Asset To Focus on More Differentiated Drugs
November 13, 2025
·
2 min read
·
Tristan Manalac
Neuroscience
Alkermes Pushes Narcolepsy Program to Phase III With ‘Highly Competitive’ Mid-Stage Data
November 13, 2025
·
2 min read
·
Tristan Manalac